Leading Tesla Supplier Claims Landmark Battery Density: Report

Tesla Inc (NASDAQ:TSLA) supplier Contemporary Amperex Technology Co Limited worked on new battery materials that can improve energy density by 10%…
  • Tesla Inc (NASDAQ:TSLA) supplier Contemporary Amperex Technology Co Limited worked on new battery materials that can improve energy density by 10% – 20% compared to iron phosphate batteries, Reuters reports citing CATL Chair.
  • The new material technology, M3P, can enable an electric vehicle to run 700 km (430 miles) per charge combined with CATL’s next generation of battery pack technology, Zeng Yuqun said at Beijing’s World New Energy Vehicle Congress.
  • The new materials will also lower the costs compared to nickel and cobalt-based batteries increasing its edge over LG Energy Solution and BYD Co, Ltd (OTC:BYDDY).
  • Also Read: Prominent Tesla Supplier CATL Announces Major Management Reshuffle As Co-Founder Quits
  • China expects the global market size of EV batteries to reach $250 billion by 2030.
  • CATL will supply Qilin batteries with its latest battery pack technology to power Geely Automobile Holdings Ltd’s (OTC:GELYY) Zeekr cars due to hit the market in early 2023.
  • CALT launched the Qilin battery in June, claiming a 13% higher energy density than Tesla’s 4680 cylindrical battery cells.
  • CATL, whose other clients included Volkswagen AG (OTC: VWAGY), Bayerische Motoren Werke AG (OTC: BMWYY), and Ford Motor Co (NYSE: F), accounts for over a third of the sales of batteries for global electric vehicles.
  • CATL explored setting up manufacturing plants in the U.S.
  • Nissan Leaf battery pack photo via Wikimedia Commons
Total
0
Shares
Related Posts
Read More

Castle Biosciences Announces Results From A Randomized Controlled Trial Show That TissueCypher Barrett’s Esophagus Test Results Can Significantly Improve The Accuracy Of Risk Assessments And Adherence To Guideline-recommended Patient Management

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a randomized controlled trial (RCT) showing that use of TissueCypher®

CSTL